The team at Seaport Therapeutics, a Boston neuropsychiatry biotech, is having a good fall season.
Seaport said Monday it has pieced together $225 million from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.